Pierre Regent Leblanc, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 3 | 2019 | 41 | 0.840 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2018 | 404 | 0.640 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2015 | 70 | 0.520 |
Why?
|
| Avidin | 1 | 2014 | 44 | 0.480 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2014 | 156 | 0.470 |
Why?
|
| Lassa Fever | 1 | 2014 | 97 | 0.440 |
Why?
|
| Parkinson Disease | 5 | 2023 | 2774 | 0.340 |
Why?
|
| Viral Vaccines | 1 | 2014 | 636 | 0.310 |
Why?
|
| Antibodies | 1 | 2015 | 2459 | 0.290 |
Why?
|
| Drug Approval | 1 | 2012 | 740 | 0.270 |
Why?
|
| Drug Discovery | 2 | 2016 | 1057 | 0.260 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 3843 | 0.230 |
Why?
|
| Vaccines | 1 | 2012 | 817 | 0.230 |
Why?
|
| Pluripotent Stem Cells | 2 | 2022 | 795 | 0.220 |
Why?
|
| Aphakia | 1 | 2022 | 24 | 0.210 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2023 | 375 | 0.210 |
Why?
|
| Dopamine | 4 | 2023 | 1589 | 0.200 |
Why?
|
| Sirtuin 2 | 1 | 2021 | 97 | 0.200 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2023 | 1728 | 0.200 |
Why?
|
| Dynamins | 1 | 2021 | 152 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 480 | 0.180 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2021 | 337 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 489 | 0.180 |
Why?
|
| Cancer Vaccines | 2 | 2018 | 1021 | 0.170 |
Why?
|
| Antibody Specificity | 3 | 2015 | 1094 | 0.160 |
Why?
|
| Chloroquine | 1 | 2019 | 280 | 0.160 |
Why?
|
| Influenza Vaccines | 2 | 2017 | 733 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3770 | 0.150 |
Why?
|
| Injections, Intradermal | 1 | 2017 | 117 | 0.150 |
Why?
|
| Lasers, Semiconductor | 1 | 2017 | 46 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2019 | 514 | 0.150 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 249 | 0.140 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 434 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2023 | 2986 | 0.140 |
Why?
|
| Staphylococcal Protein A | 1 | 2015 | 40 | 0.140 |
Why?
|
| Immobilized Proteins | 1 | 2015 | 25 | 0.140 |
Why?
|
| Antiparkinson Agents | 1 | 2016 | 183 | 0.130 |
Why?
|
| Fibroblasts | 2 | 2022 | 4143 | 0.120 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 549 | 0.120 |
Why?
|
| HLA-DR3 Antigen | 1 | 2014 | 34 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 540 | 0.120 |
Why?
|
| Cross Reactions | 1 | 2015 | 841 | 0.110 |
Why?
|
| Vaccination | 2 | 2017 | 3256 | 0.110 |
Why?
|
| Lassa virus | 1 | 2014 | 97 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2502 | 0.110 |
Why?
|
| Graft Survival | 1 | 2023 | 3733 | 0.110 |
Why?
|
| Infrared Rays | 1 | 2013 | 249 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1613 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 2018 | 1170 | 0.100 |
Why?
|
| Ovalbumin | 1 | 2014 | 719 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2018 | 818 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 248 | 0.100 |
Why?
|
| Immunocompetence | 1 | 2011 | 137 | 0.100 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2011 | 75 | 0.100 |
Why?
|
| Quinolines | 1 | 2016 | 719 | 0.100 |
Why?
|
| Mesencephalon | 2 | 2023 | 327 | 0.090 |
Why?
|
| Drug Design | 1 | 2016 | 1078 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2013 | 456 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2014 | 541 | 0.090 |
Why?
|
| RNA Splice Sites | 1 | 2011 | 209 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 457 | 0.090 |
Why?
|
| Lasers | 1 | 2013 | 952 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 462 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1618 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2011 | 3465 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2011 | 952 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 1000 | 0.080 |
Why?
|
| Norepinephrine | 1 | 2011 | 909 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 9735 | 0.080 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 436 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2130 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1983 | 0.070 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2011 | 570 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2011 | 726 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 21821 | 0.070 |
Why?
|
| Simian immunodeficiency virus | 1 | 2011 | 846 | 0.070 |
Why?
|
| Animals | 14 | 2023 | 168561 | 0.060 |
Why?
|
| Mice | 9 | 2023 | 81045 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2014 | 3199 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 18006 | 0.060 |
Why?
|
| Oxidopamine | 1 | 2023 | 169 | 0.060 |
Why?
|
| Spleen | 1 | 2009 | 2359 | 0.060 |
Why?
|
| Cricetulus | 2 | 2018 | 817 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 1825 | 0.060 |
Why?
|
| Cell Death | 2 | 2023 | 1695 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 2038 | 0.050 |
Why?
|
| CHO Cells | 2 | 2018 | 1407 | 0.050 |
Why?
|
| Neostriatum | 1 | 2023 | 250 | 0.050 |
Why?
|
| Hippocampus | 1 | 2014 | 3661 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 3574 | 0.050 |
Why?
|
| Levodopa | 1 | 2022 | 218 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4465 | 0.050 |
Why?
|
| Rats | 3 | 2023 | 24265 | 0.050 |
Why?
|
| Cricetinae | 2 | 2018 | 2471 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 4379 | 0.050 |
Why?
|
| Brain | 2 | 2020 | 26343 | 0.050 |
Why?
|
| Substantia Nigra | 1 | 2022 | 353 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 3564 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 480 | 0.040 |
Why?
|
| Putamen | 1 | 2020 | 291 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2022 | 11470 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 1085 | 0.040 |
Why?
|
| Mitochondria | 2 | 2022 | 3520 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 5705 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 825 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2020 | 545 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 226 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2012 | 4414 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2011 | 13029 | 0.030 |
Why?
|
| Humans | 16 | 2023 | 742088 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2123 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2014 | 69 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 2715 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4823 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1791 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2019 | 765 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 2417 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2023 | 10472 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2019 | 1348 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 4771 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2022 | 5975 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1799 | 0.020 |
Why?
|
| Female | 8 | 2022 | 379592 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2896 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2011 | 337 | 0.020 |
Why?
|
| Cryoprotective Agents | 1 | 2011 | 111 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 2837 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2014 | 2257 | 0.020 |
Why?
|
| Glycerol | 1 | 2011 | 278 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 544 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3760 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 497 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 3617 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2011 | 257 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2011 | 607 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2011 | 670 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 1820 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 822 | 0.020 |
Why?
|
| Time Factors | 2 | 2023 | 40054 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1655 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 29717 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8621 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 20774 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 1988 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2011 | 1144 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2011 | 2378 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6259 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3862 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2023 | 62966 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 1221 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 16678 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 13814 | 0.010 |
Why?
|
| RNA Interference | 1 | 2011 | 2890 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2022 | 12164 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 10163 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16665 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 18112 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2011 | 4024 | 0.010 |
Why?
|
| Skin | 1 | 2013 | 4353 | 0.010 |
Why?
|
| Inflammation | 1 | 2019 | 10578 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39004 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 13256 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20086 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12773 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23387 | 0.010 |
Why?
|
| Male | 3 | 2022 | 349538 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 9715 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2009 | 9144 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 7988 | 0.010 |
Why?
|
| Aged | 2 | 2020 | 162944 | 0.010 |
Why?
|
| Neoplasms | 1 | 2014 | 21596 | 0.000 |
Why?
|
| Middle Aged | 1 | 2009 | 213127 | 0.000 |
Why?
|